Clinical Rheumatology

, Volume 26, Issue 8, pp 1383–1385 | Cite as

Successful treatment of life-threatening intestinal ulcer in Behçet’s disease with infliximab: rapid healing of Behçet’s ulcer with infliximab

  • Ji Hyeon Ju
  • Seung-Ki Kwok
  • Soo-Hong Seo
  • Chong-Hyeon Yoon
  • Ho-Youn Kim
  • Sung-Hwan ParkEmail author
Case Report


Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder characterized predominantly by recurrent orogenital ulcers, skin involvement, and uveitis. Recurrent mucocutaneous lesions may be the only symptom in mild cases, but ocular, gastrointestinal, and central nervous system involvement may occur in severe cases. We report in this study the successful treatment with infliximab of severe life-threatening GI bleeding caused by an ileal ulcer in a patient with Behçet’s disease. Antitumor necrosis factor (TNF) therapy could be an emergency therapeutic option in patients with massively bleeding Behçet’s disease and unstable patients or those with acute bleeding with other TNF-α-mediated autoimmune diseases. Another option for anti-TNF therapy could be as bridging management between conservative and surgical treatment.


Behcet’s disease Gastrointestinal bleeding Ileal ulcer Infliximab 


  1. 1.
    International study group for Behçet’s disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080Google Scholar
  2. 2.
    Kasahara Y, Tanaka S, Nishino M, Umemura H, Shiraha S, Kuyama T (1981) Intestinal involvement in Behçet’s disease: review of 136 surgical cases in the Japanese literature. Dis Colon Rectum 24:103–106PubMedCrossRefGoogle Scholar
  3. 3.
    Haugeberg G, Velken M, Johnsen V (2004) Successful treatment of genital ulcers with infliximab in Behçet’s disease. Ann Rheum Dis 63:744–745PubMedCrossRefGoogle Scholar
  4. 4.
    Hassard PV, Binder SW, Nelson V, Vasiliauskas EA (2001) Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease: a case report. Gastroenterology 120:995–999PubMedCrossRefGoogle Scholar
  5. 5.
    Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296PubMedCrossRefGoogle Scholar
  6. 6.
    Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL (2001) Treatment of intestinal Behçet’s syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49:725–728PubMedCrossRefGoogle Scholar
  7. 7.
    Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1:1093–1096PubMedCrossRefGoogle Scholar
  8. 8.
    Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM (2005) Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89:533–536PubMedCrossRefGoogle Scholar
  9. 9.
    Mussack T, Landauer N, Ladurner R, Schiemann U, Goetzberger M, Burchardi C, Folwaczny C, Heldwein W, Hallfeldt K (2003) Successful treatment of cervical esophageal perforation in Behçet’s disease with drainage operation and infliximab. Am J Gastroenterol 98:703–704PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2006

Authors and Affiliations

  • Ji Hyeon Ju
    • 1
  • Seung-Ki Kwok
    • 1
  • Soo-Hong Seo
    • 1
  • Chong-Hyeon Yoon
    • 1
  • Ho-Youn Kim
    • 1
  • Sung-Hwan Park
    • 1
    • 2
    Email author
  1. 1.The Center for Rheumatic Disease, College of Medicine, Kangnam St. Mary’s HospitalThe Catholic University of KoreaSeoulSouth Korea
  2. 2.Division of Rheumatology, Department of Internal Medicine, College of MedicineThe Catholic University of KoreaSeoulSouth Korea

Personalised recommendations